Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.

Bouillet LÉ, Dias MO, Dorigo NA, Moura AD, Russell B, Nosten F, Renia L, Braga EM, Gazzinelli RT, Rodrigues MM, Soares IS, Bruna-Romero O.

Infect Immun. 2011 Sep;79(9):3642-52. doi: 10.1128/IAI.05048-11. Epub 2011 Jul 5.

2.

Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.

Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE.

Vaccine. 2004 Sep 9;22(27-28):3727-37.

PMID:
15315853
3.

Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast.

Vicentin EC, Françoso KS, Rocha MV, Iourtov D, Dos Santos FL, Kubrusly FS, Sakauchi MA, Raw I, Nosten F, Rénia L, Rodrigues MM, Russell B, Soares IS.

Infect Immun. 2014 Mar;82(3):1296-307. doi: 10.1128/IAI.01169-13. Epub 2013 Dec 30.

4.

Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.

Arévalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S.

Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):25-31.

PMID:
16291763
5.

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.

Vaccine. 2007 Jul 9;25(28):5166-74. Epub 2007 May 21.

PMID:
17544179
6.

Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.

Mehrizi AA, Zakeri S, Rafati S, Salmanian AH, Djadid ND.

Parasite Immunol. 2011 Nov;33(11):594-608. doi: 10.1111/j.1365-3024.2011.01331.x.

7.
8.

Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.

Giraldo MA, Arevalo-Pinzon G, Rojas-Caraballo J, Mongui A, Rodriguez R, Patarroyo MA.

Vaccine. 2009 Dec 10;28(1):7-13. doi: 10.1016/j.vaccine.2009.09.046. Epub 2009 Sep 25.

PMID:
19782110
10.

Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.

Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabongkot J, Torii M, Tsuboi T, Kumar N.

Vaccine. 2004 Aug 13;22(23-24):3205-13.

PMID:
15297075
11.

Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.

Almeida AP, Dias MO, Vieira Cde A, Chávez-Olórtegui C, Gazzineli RT, Rodrigues MM, Fujiwara RT, Bruna-Romero O.

Vaccine. 2014 Apr 17;32(19):2181-7. doi: 10.1016/j.vaccine.2014.02.053. Epub 2014 Feb 28.

PMID:
24582631
12.

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.

J Immunol. 2010 Dec 15;185(12):7583-95. doi: 10.4049/jimmunol.1001760. Epub 2010 Nov 22.

13.

Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.

Arévalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincón A, Saul A, Mu J, Long C, Miller L, Herrera S.

Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):32-7.

PMID:
16291764
14.

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.

Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Stürchler D.

Vaccine. 1999 Aug 6;17(23-24):3145-59.

PMID:
10462251
15.

Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.

Lalitha PV, Biswas S, Pillai CR, Saxena RK.

Vaccine. 2008 Aug 18;26(35):4526-35. doi: 10.1016/j.vaccine.2008.06.031. Epub 2008 Jun 30.

PMID:
18590786
16.

Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-119 on the innate immune response.

Bueno LL, Fujiwara RT, Soares IS, Braga EM.

Vaccine. 2008 Feb 26;26(9):1204-13. doi: 10.1016/j.vaccine.2007.12.031. Epub 2008 Jan 14.

PMID:
18242795
17.

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A.

Vaccine. 2012 May 9;30(22):3311-9. doi: 10.1016/j.vaccine.2012.03.004. Epub 2012 Mar 13.

PMID:
22425788
18.

Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.

Saul A, Hensmann M, Sattabongkot J, Collins WE, Barnwell JW, Langermans JA, Wu Y, Long CA, Dubovsky F, Thomas AW.

Parasite Immunol. 2007 Oct;29(10):525-33.

19.

Plasmodium vivax apical membrane antigen-1: comparative recognition of different domains by antibodies induced during natural human infection.

Múfalo BC, Gentil F, Bargieri DY, Costa FT, Rodrigues MM, Soares IS.

Microbes Infect. 2008 Oct;10(12-13):1266-73. doi: 10.1016/j.micinf.2008.07.023. Epub 2008 Jul 22.

PMID:
18692152
20.

A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice.

Gentil F, Bargieri DY, Leite JA, Françoso KS, Patricio MB, Espíndola NM, Vaz AJ, Palatnik-de-Sousa CB, Rodrigues MM, Costa FT, Soares IS.

Vaccine. 2010 Aug 31;28(38):6183-90. doi: 10.1016/j.vaccine.2010.07.017. Epub 2010 Jul 21.

PMID:
20654667

Supplemental Content

Support Center